Skip to main content

FDA

FDA Weighs Easing Tobacco Product Review Amid 7,500 Illegal Items

FDA Weighs Easing Tobacco Product Review Amid 7,500 Illegal Items

Washington – September 28, 2026 -- The U.S. Food and Drug Administration announced plans to evaluate changes to its application framework for new tobacco products, including e-cigarettes and nicotine pouches, aiming to simplify the pathway for these products to reach the market.

Truth Initiative warns weakened review could undermine public health protections

Kathy Crosby, CEO and President of Truth Initiative, said any changes that reduce the scientific evidence required or diminish the review process would compromise the FDA's regulatory role. The law currently requires the agency to assess a product's components, ingredients, toxicological profile and health impact, alongside risks and benefits to the broader population, including youth and non-users.

FDA Aftershock and Strategic Signals: What 2026 Could Mean for Regulated Industries

FDA Aftershock and Strategic Signals: What 2026 Could Mean for Regulated Industries

SHERIDAN, WYOMING - February 10, 2026 - The U.S. Food and Drug Administration entered 2026 fundamentally reshaped after a year of unprecedented leadership turnover, shifting regulatory priorities, and workforce reductions under the second Trump administration. Developments throughout 2025 altered both risk profiles and opportunity structures for companies operating in pharmaceuticals, biologics, medical devices, and regulated food markets. For executives and regulatory leaders, understanding how these changes converged is now essential for planning submissions, investments, and compliance strategies in the year ahead.

Subscribe to FDA